• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

14.50 -0.44 (-2.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 12, 2025
From Travere Therapeutics, Inc.
Via Business Wire
7 Analysts Assess Travere Therapeutics: What You Need To Know
June 11, 2025
Via Benzinga
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
June 11, 2025
From Travere Therapeutics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
June 10, 2025
From Pomerantz LLP
Via GlobeNewswire
Earnings Scheduled For May 1, 2025
May 01, 2025
Via Benzinga
Travere Therapeutics's Earnings: A Preview
April 30, 2025
Via Benzinga
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
June 10, 2025
From Travere Therapeutics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
June 06, 2025
From Pomerantz LLP
Via GlobeNewswire
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
June 03, 2025
From Travere Therapeutics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
June 02, 2025
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
May 28, 2025
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
May 22, 2025
From Pomerantz LLP
Via GlobeNewswire
Globant, Doximity, Applied Materials And Other Big Stocks Moving Lower In Friday's Pre-Market Session
May 16, 2025
Via Benzinga
IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why
May 16, 2025
Analysts are still bullish on the company's chances of being the first to win approval for an FSGS drug. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Top movers in Friday's pre-market session
May 16, 2025
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 16, 2025
Via Benzinga
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
May 16, 2025
Via Benzinga
Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries
May 16, 2025
Under the Prescription Drug User Fee Act, the agency has now set a target action date of Jan. 13, 2026. 
Via Stocktwits
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
May 15, 2025
Via Benzinga
Thursday's after hours session: top gainers and losers
May 15, 2025
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
May 15, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
May 13, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics to Participate at Upcoming Investor Conferences
May 07, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Is TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) following the Minervini trend for explosive growth?
May 02, 2025
Should you consider TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) for high growth investing? A fundamental and technical analysis of (NASDAQ:TVTX). 
Via Chartmill
Travere Therapeutics Reports First Quarter 2025 Financial Results
May 01, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
April 29, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics to Report First Quarter 2025 Financial Results
April 24, 2025
From Travere Therapeutics, Inc.
Via Business Wire
Assessing Travere Therapeutics: Insights From 8 Financial Analysts
April 23, 2025
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2025
From Travere Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap